Results 161 to 170 of about 19,806 (216)

Liquid biopsy: a new window on the BRCA genes. [PDF]

ESMO Open
Incorvaia L, Gristina V, Pepe F, Bazan Russo TD, Santoni M, Mujacic C, Curigliano G, Malapelle U, Capoluongo ED, Russo A.   +9 more
europepmc   +1 more source

Real-world utilization patterns and association of dd-cfDNA with biopsy and rejection. [PDF]

Front Med (Lausanne)
Dedinská I, Akifova A, Osmanodja B, Halleck F, Schrezenmeier EV, Avaniadi P, Čereš A, Vnucak M, Granak K, Beck J, Bornemann-Kolatzki K, Oellerich M, Schuetz E, Budde K.   +13 more
europepmc   +1 more source

Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring. [PDF]

Blood Adv
Piffaretti D, Consoli C, Rossi D.
europepmc   +1 more source

Epigenomic modifications define chromatin states to regulate cell-free DNA fragmentomics. [PDF]

Nat Commun
Gong F, Pan Y, Lin H, An Y, Yang M, Liu X, Bai Y, Zhang Z, Tang B, Zhang K, Zhao X, Zhao Y, Du C, Shen X, Sun K.   +14 more
europepmc   +1 more source

The Landscape of Biomarkers in ICU-Associated AKI: From Protein Markers to Cell-Free Nucleic Acids. [PDF]

J Clin Lab Anal
Zhu Q, Yang F, Zheng H, Guo X, Chen Z, Chen L, Wang D, Wang J, Wang X, Huang Z, Ji Z.   +10 more
europepmc   +1 more source

Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience. [PDF]

Genome Med
Maass KK, Puranachot P, Volz S, Schad PS, Finster AME, Fischer TT, Jones BC, Schramm K, Henneken SC, Simon N, Montigel SH, Wedig T, Schwarz N, Zuliani C, Fiesel P, Previti C, Balasubramanian G, Iser F, Meyer J, van Tilburg CM, Milde T, Witt O, Rossi C, Sparber-Sauer M, Zimmermann S, Lehrnbecher T, Lauten M, Sill M, Jäger N, Autry RJ, Northcott PA, Sahm F, Jones DTW, Pfister SM, Brors B, Pajtler KW.   +35 more
europepmc   +1 more source

Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma. [PDF]

Blood Adv
Li C, Chen X, Xu J, Lei T, Yu H, Peng S, Han S, Yang H.   +7 more
europepmc   +1 more source

Microfluidic Technologies for cfDNA Isolation and Analysis [PDF]

Micromachines, 2019
Cell-free DNA (cfDNA), which promotes precision oncology, has received extensive concern because of its abilities to inform genomic mutations, tumor burden and drug resistance. The absolute quantification of cfDNA concentration has been proved as an independent prognostic biomarker of overall survival.
Jing Tu, Yi Qiao
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

The personal utility of cfDNA screening: Pregnant patients' experiences with cfDNA screening and views on expanded cfDNA panels

Journal of Genetic Counseling, 2019
AbstractPrenatal cell‐free DNA screening (cfDNA) provides more genetic risk information about the fetus than has ever been possible. At the same time, the rapid expansion of new cfDNA panels raises important questions about how to structure patient‐centered discussions that best support patients' decision‐making about its use. To address this question,
Ruth M, Farrell, Patricia K, Agatisa, Marsha M, Michie, Amy, Greene, Paul J, Ford   +4 more
openaire   +2 more sources

Association of cfDNA levels and bothrops envenomation

Toxicon, 2021
In the Amazon, around 90% of snakebites are caused by the Bothrops genus. Complications arising from Bothrops envenomations result from the inflammatory and coagulotoxic activities of the venom. The aim of this study was to investigate the potential of cell-free DNA (cfDNA) as a biomarker of severity in Bothrops snakebites. Patients were treated at the
Êndila, de Souza Barbosa, Hiochelson Najibe, Santos Ibiapina, Siuhelem, Rocha da Silva, Allyson Guimarães, Costa, Fernando Fonseca, Val, Iran, Mendonça-da-Silva, Luiz, Carlos de Lima Ferreira, Marco Aurélio, Sartim, Wuelton Marcelo, Monteiro, Gisely, Cardoso de Melo, Jacqueline, de Almeida Gonçalves Sachett   +10 more
openaire   +2 more sources